REDWOOD CITY, Calif., July 7 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the appointment of Sunil Patel to the position of Senior Vice President, Corporate Development. In this new position, Mr. Patel will have primary responsibility for corporate business development activities, reporting directly to Paul Hastings, OncoMed’s President and Chief Executive Officer.
“We are pleased to welcome Sunil to the OncoMed management team. His track record in strategic deal making, particularly in the field of oncology drug discovery and development, make him a great addition,” said Mr. Hastings. “Sunil’s wealth of corporate development expertise will be an important asset for OncoMed as we discover novel anti-cancer stem cell therapeutics and advance our product candidates into clinical development.”
Mr. Patel brings more than 15 years of biopharmaceuticals industry experience to his new role at OncoMed. He joins OncoMed from BiPar Sciences where as Vice President, Corporate Development and Marketing he led the sale of that company to Sanofi-Aventis in April of this year. Previously, he held senior corporate development, marketing, and strategy positions with Allos Therapeutics, Connetics Corporation, Abgenix and Gilead Sciences. Mr. Patel also served as a consultant with McKinsey & Company. Earlier in his career, he was a researcher at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and his master’s degree in Molecular Bioengineering/Biotechnology at the University of Washington.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed’s lead candidate, OMP-21M18 is currently in Phase I clinical trials. Privately-held, OncoMed’s investors include: Nomura Phase4 Ventures, US Venture Partners, Latterell Venture Partners, Morgenthaler Ventures, The Vertical Group, Adams Street Partners, De Novo Ventures, Delphi Ventures, Bay Partners and GlaxoSmithKline. Additional information can be found at the company’s website: www.oncomed.com.
CONTACT: Paul Hastings, President and Chief Executive Officer,
phastings@oncomed.com, or William D. Waddill, Senior Vice President, Chief
Financial Officer, william.waddill@oncomed.com, both of OncoMed
Pharmaceuticals, Inc., +1-650-995-8200; or Karen L. Bergman,
+1-650-575-1509, kbergman@bccpartners.com, or Michelle Corral,
+1-415-794-8662, mcorral@bccpartners.com, both of BCC Partners, for OncoMed
Pharmaceuticals, Inc.
Web site: http://www.oncomed.com/
